Palbociclib + Letrozole Improves PFS in ER+, HER2- Advanced Breast Cancer

Share this content:
Adding palbociclib to letrozole significantly improved progression-free survival compared with letrozole alone.
Adding palbociclib to letrozole significantly improved progression-free survival compared with letrozole alone.

Adding palbociclib to letrozole significantly improved progression-free survival compared with letrozole alone among patients with previously untreated estrogen receptor (ER)-positive, HER2-negative advanced breast cancer, according to findings published in The New England Journal of Medicine.1

The phase 2 PALOMA-1/TRIO-18 study demonstrated that progression-free survival was longer with the cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole than letrozole alone in the first-line treatment of postmenopausal women with ER-positive, HER2-negative advanced breast cancer. To confirm and expand the efficacy and safety data for this combination in this patient population, researchers designed the double-blind, phase 3 PALOMA-2 trial (ClinicalTrials.gov Identifier, NCT01740427).

Investigators enrolled 666 postmenopausal women with newly diagnosed ER-positive, HER2-negative breast cancer who had not received prior treatment for advanced disease. Participants were randomly assigned 2:1 to receive palbociclib in combination with letrozole or letrozole plus placebo.

After a median follow-up of 23 months, researchers found that the combination of palbociclib and letrozole reduced the risk of progression or death by 42% (hazard ratio, 0.58; 95% CI, 0.46-0.72; P < .001) compared with letrozole alone; median progression-free survival was 24.8 months (95% CI, 22.1-not estimable) and 14.5 months (95% CI, 12.9-17.1), respectively.

The confirmed objective response rate among patients assigned to the palbociclib-letrozole group was 42.1% (95% CI, 37.5-46.9) overall vs 34.7% (95% CI, 28.4-41.3) in the letrozole arm. Among those with measurable disease, the confirmed objective response rate was 55.3% (95% CI, 49.9-60.7) with palbociclib-letrozole and 44.4% (95% CI, 36.9-52.2) with letrozole-placebo.

Patients in the palbociclib plus letrozole arm more frequently reported grade 3 or 4 neutropenia, leukopenia, anemia, and fatigue. Approximately 2% of patients experienced febrile neutropenia in the combination arm vs no patients in the letrozole arm.

RELATED: Breast Cancers With PIK3CA Mutations May Derive Greater Benefit From Letrozole

Findings from the PALOMA-2 trial confirmed the earlier results of PALOMA-1. Although the addition of palbociclib was associated with higher rates of myelotoxicity, investigators have been able to successfully manage these effects with appropriate supportive care and dose reductions.

Reference

  1. Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925-36. doi: 10.1056/NEJMoa1607303

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters